Orbitrap Excedion Pro BioPharma Mass Spectrometer and UHPLC
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
FDA OFFICE OF ACQ GRANT SVCS
Contract Value
Not provided
Codes & Classification
Solicitation Number
75F40126Q00088
NAICS
334516 - Analytical Laboratory Instrument Manufacturing
Classification Code
6640
Additional Details
Documents1
The Food and Drug Administration (FDA), operating under the Department of Health and Human Services, has issued a combined synopsis/solicitation for the acquisition of a high-resolution mass spectrometry system with integrated ultra-high-performance liquid chromatography (UHPLC) capabilities. This procurement is intended to enhance the FDA’s analytical capacity for pharmaceutical drug substance and product evaluation, with a particular focus on the detection and characterization of nitrosamine impurities, small molecules, peptides, and other biomolecules. The Thermo Scientific Orbitrap Excedion Pro BioPharma Mass Spectrometer and UHPLC system is referenced as the benchmark for performance and functionality, though the solicitation is open to brand-name or equivalent products.
The scope of this acquisition encompasses the delivery, installation, and qualification (IQ/OQ) of a fully integrated LC-MS analytical system at the FDA facility in Saint Louis, Missouri. The system must be capable of supporting regulatory-grade analytical workflows, providing high-resolution, accurate-mass detection across a broad mass range (minimum up to m/z 12,000), and offering sensitivity sufficient for trace-level impurity detection, including nitrosamines. Compatibility with biocompatible UHPLC applications is required, as is the inclusion of advanced instrument control and data analysis software to facilitate automated data processing, spectral deconvolution, and identification workflows for complex pharmaceutical samples. Centralized data management, secure instrument operation, workflow automation, and laboratory data integration are also essential deliverables.
Key requirements for the system include:
- High-resolution accurate-mass (HRAM) mass spectrometry capable of resolving complex mixtures and trace-level impurities.
- Mass analyzer with resolving power adequate for high-confidence molecular identification and impurity characterization.
- Extended mass range to support both small molecule and biomolecule analysis.
- Integrated UHPLC system suitable for biocompatible analytical workflows.
- Advanced software for instrument control, data analysis, and workflow automation.
- Automated data processing and spectral deconvolution capabilities.
- Secure, centralized data management and laboratory integration.
- Delivery, installation, and instrument qualification services.
- Vendor-provided instrument familiarization and operational training.
- Minimum one-year manufacturer warranty covering parts, labor, travel, and OEM-certified service support, commencing upon Government acceptance.
Offerors may propose either the referenced brand-name system or an equivalent product, provided that all salient characteristics are met or exceeded. Proposals for equivalent products must clearly demonstrate compliance with each requirement to be considered technically acceptable.
This procurement is classified under NAICS code 334516 (Analytical Laboratory Instrument Manufacturing, 2022 version) and Product Service Code 6640. The opportunity is set aside for Small Business Administration (SBA) eligible entities, reflecting the FDA’s commitment to supporting small business participation in federal contracting.
The place of performance is Saint Louis, Missouri, United States. The contracting entity is the FDA Office of Acquisition and Grant Services. Interested parties may direct inquiries to the primary contact, Reagan Davis, at [email protected] or 301-796-0910.
The solicitation was posted on June 5, 2026, and responses are due by July 5, 2026. The notice remains active and is accessible via SAM.gov at https://sam.gov/opp/daa8b5446379478e9536342d5cd69982/view.
Contractors with expertise in analytical laboratory instrument manufacturing and the ability to deliver high-performance LC-MS systems with the specified capabilities are encouraged to review the solicitation and consider submitting a quotation. The requirements outlined are expected to remain constant throughout the contract lifecycle, ensuring consistent support for the FDA’s pharmaceutical quality evaluation and impurity characterization objectives.